Given the apparent involvement of TFAP2A in the MAPK pathway, the impact of TFAP2A overexpression on the responsiveness of tumour cells to osimertinib, a first-line targeted drug for NSCLC patients, was investigated. Here, TFAP2A is linked to non-small cell lung carcinoma.